AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25440324 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month community-based structured program including 2 sessions of exercise training and 1 session of recreation and leisure activities per week (INT; n = 12)
Number of subjects: 28
Study 25440324 — intervention group
Group type: COMPARATOR
Intervention: Usual care (D-INT; n = 16)
Number of subjects: 28
Study 25822778 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for ARDS patients requiring mechanical ventilation
Number of subjects: 282
Study 22901493 — intervention group
Group type: EXPERIMENTAL
Intervention: telephone support (n=241)
Number of subjects: 423
Study 22901493 — intervention group
Group type: COMPARATOR
Intervention: home visit (n=182)
Number of subjects: 423
Study 21310305 — intervention group
Group type: COMPARATOR
Intervention: 0 g of mixed fibers
Number of subjects: 20
Study 21310305 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of mixed fibers
Number of subjects: 20
Study 21310305 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g of mixed fibers
Number of subjects: 20
Study 21310305 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g of mixed fibers
Number of subjects: 20
Study 20027554 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-end anastomosis to the internal iliac artery
Number of subjects: 38
Study 20027554 — intervention group
Group type: COMPARATOR
Intervention: End-to-side anastomosis to the external iliac artery
Number of subjects: 38
Study 16489964 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based course for community nurses focusing on evidence-based interventions for postpartum emotional distress
Number of subjects: 22
Study 16489964 — intervention group
Group type: COMPARATOR
Intervention: Control group (no web-based course)
Number of subjects: 22
Study 16489964 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based course for community nurses
Number of subjects: 22
Study 16489964 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental centres
Number of subjects: 22
Study 14579209 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Support Ventilation (ASV)
Number of subjects: 155
Study 11124007 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.33% glyceryl trinitrate
Number of subjects: 200
Study 11124007 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% capsaicin
Number of subjects: 200
Study 11124007 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% capsaicin + 1.33% glyceryl trinitrate
Number of subjects: 200
Study 11124007 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 200
Study 9804219 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized 17beta‐oestradiol 4 mg/day with GnRHa suppression
Number of subjects: 106
Study 9804219 — intervention group
Group type: COMPARATOR
Intervention: Micronized 17beta‐oestradiol 6 mg/day without GnRHa suppression
Number of subjects: 106
Study 8014529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) ketorolac 60 mg (2 mL)
Number of subjects: 30
Study 8014529 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 2 mL, IM (Control)
Number of subjects: 30
Study 2809913 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D2 supplementation (2000 IU/day)
Number of subjects: 81
Study 2809913 — intervention group
Group type: COMPARATOR
Intervention: Control group (400 IU/day vitamin D2)
Number of subjects: 81
Study 973749 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal Cell Vagotomy (PCV)
Number of subjects: 92
Study 973749 — intervention group
Group type: COMPARATOR
Intervention: Selective vagotomy-antrectomy Billroth I (SV‐A‐BI)
Number of subjects: 92
Study 30371146 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 mg/day of GRE for 3 days
Number of subjects: 11
Study 30371146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gluten-free cornstarch)
Number of subjects: 11
Study 29158595 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-resistant strains
Number of subjects: 3324
Study 29158595 — intervention group
Group type: EXPERIMENTAL
Intervention: Different developmental stages
Number of subjects: 3324
Study 25400162 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 535
Study 25400162 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 535
Study 22006095 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 156
Study 21586712 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole, 20 to 40 mg/d
Number of subjects: 554
Study 21586712 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic antireflux surgery (LARS)
Number of subjects: 554
Study 21586712 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 554
Study 21586712 — intervention group
Group type: COMPARATOR
Intervention: LARS
Number of subjects: 554
Study 19376152 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape-frequency after-effects (SFAE)
Number of subjects: 0
Study 19376152 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape-amplitude after-effects (SAAE)
Number of subjects: 0
Study 19376152 — intervention group
Group type: EXPERIMENTAL
Intervention: SFAE and SAAE
Number of subjects: 0
Study 19376152 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in SFAE and SAAE from texture-surround inhibition
Number of subjects: 0
Study 16551904 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 40
Study 16551904 — intervention group
Group type: COMPARATOR
Intervention: Propofol with 67% nitrous oxide (N2O)
Number of subjects: 40
Study 12919758 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAVE
Number of subjects: 178
Study 12919758 — intervention group
Group type: COMPARATOR
Intervention: COS
Number of subjects: 178
Study 10653385 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 32
Study 10653385 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune (SIM)
Number of subjects: 32
Study 10173369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal triamcinolone acetonide (220 micrograms/day)
Number of subjects: 0
Study 10173369 — intervention group
Group type: COMPARATOR
Intervention: Oral loratadine (10 mg/day)
Number of subjects: 0
Study 10173369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal triamcinolone acetonide
Number of subjects: 0
Study 10173369 — intervention group
Group type: COMPARATOR
Intervention: Oral loratadine
Number of subjects: 0
Study 10173369 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study 10173369 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' global evaluations
Number of subjects: 0
Study 8523374 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER (mean daily dose 11.2 mg)
Number of subjects: 118
Study 8523374 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (mean daily dose 7.4 mg)
Number of subjects: 118
Study 8523374 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER
Number of subjects: 118
Study 8523374 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 118
Study 2492354 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachable subcutaneous cuff
Number of subjects: 55
Study 2492354 — intervention group
Group type: COMPARATOR
Intervention: Control (no cuff)
Number of subjects: 55
Study 2492354 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyantibiotic ointment
Number of subjects: 55
Study 31080037 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein/low carbohydrate diet (Diet HP)
Number of subjects: 268
Study 31080037 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hypocaloric diet (Diet S)
Number of subjects: 268
Study 30641348 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 737
Study 30641348 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet based cognitive‐behavioral therapy
Number of subjects: 737
Study 30641348 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 737
Study 30641348 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination with antidepressants
Number of subjects: 737
Study 28207055 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednets (ITNs) distributed at a positive price (increased by $0.55)
Number of subjects: 0
Study 28207055 — intervention group
Group type: EXPERIMENTAL
Intervention: Households eligible for free ITNs
Number of subjects: 0
Study 28207055 — intervention group
Group type: EXPERIMENTAL
Intervention: Households paying for ITNs
Number of subjects: 0
Study 28207055 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially subsidized ITNs
Number of subjects: 0
Study 28207055 — intervention group
Group type: EXPERIMENTAL
Intervention: ITNs distributed for free or at a small nominal price
Number of subjects: 0
Study 25347682 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking workstation
Number of subjects: 180
Study 25347682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling workstation
Number of subjects: 180
Study 25347682 — intervention group
Group type: COMPARATOR
Intervention: Seated workstation
Number of subjects: 180
Study 25347682 — intervention group
Group type: COMPARATOR
Intervention: Standing workstation
Number of subjects: 180
Study 22807519 — intervention group
Group type: EXPERIMENTAL
Intervention: Balapiravir 1500 mg
Number of subjects: 64
Study 22807519 — intervention group
Group type: EXPERIMENTAL
Intervention: Balapiravir 3000 mg
Number of subjects: 64
Study 22807519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 20978101 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemia (glucose clamped to 5 mmol/l)
Number of subjects: 7
Study 20978101 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (glucose clamped to 11 mmol/l)
Number of subjects: 7
Study 19018048 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 600
Study 19018048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 16848150 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior rectus sheath method
Number of subjects: 62
Study 16848150 — intervention group
Group type: COMPARATOR
Intervention: Standard mesh repair (Lichtenstein repair)
Number of subjects: 62
Study 16848150 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (anterior rectus sheath and standard mesh repair)
Number of subjects: 62
Study 12556014 — intervention group
Group type: EXPERIMENTAL
Intervention: Airmax 6 microg, 12 microg, 24 microg, 48 microg
Number of subjects: 31
Study 12556014 — intervention group
Group type: COMPARATOR
Intervention: Foradil Aeroliser 12 microg, 24 microg, 48 microg, 96 microg
Number of subjects: 31
Study 10661337 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment with 5-fluorouracil (5-FU) and local-regional radiation
Number of subjects: 65
Study 10661337 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 65
Study 9488232 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation
Number of subjects: 64
Study 8097214 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem (25 mg twice daily during tapering)
Number of subjects: 25
Study 8097214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8097214 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem
Number of subjects: 25
Study 3991284 — intervention group
Group type: EXPERIMENTAL
Intervention: Insurance plans requiring families to pay a percentage of costs (up to 95% coinsurance)
Number of subjects: 1844
Study 3991284 — intervention group
Group type: COMPARATOR
Intervention: Free care insurance plan
Number of subjects: 1844
Study 3991284 — intervention group
Group type: EXPERIMENTAL
Intervention: Insurance plans requiring families to pay a percentage of costs
Number of subjects: 1844
Study 31053125 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-session peer group training focusing on identifying and addressing barriers to using the guideline
Number of subjects: 66
Study 31053125 — intervention group
Group type: COMPARATOR
Intervention: Traditional guideline dissemination (control group)
Number of subjects: 66
Study 30249424 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV (high D antigen content)
Number of subjects: 60
Study 30249424 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV (medium D antigen content)
Number of subjects: 60
Study 30249424 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV (low D antigen content)
Number of subjects: 60
Study 30249424 — intervention group
Group type: COMPARATOR
Intervention: cIPV
Number of subjects: 60
Study 30249424 — intervention group
Group type: COMPARATOR
Intervention: sIPV (CAMS)
Number of subjects: 60
Study 25257975 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥4 SLC2A9 minor alleles
Number of subjects: 808
Study 25257975 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC2A9 score increase
Number of subjects: 808
Study 25257975 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg/dl genetically conferred decrease in serum urate
Number of subjects: 808
Study 25257975 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg/dl measured decrease in serum urate
Number of subjects: 808
Study 22738443 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 165
Study 22738443 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 165
Study 20660284 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesperidin (800 mg/day)
Number of subjects: 204
Study 20660284 — intervention group
Group type: EXPERIMENTAL
Intervention: Naringin (500 mg/day)
Number of subjects: 204
Study 20660284 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 204
Study 20660284 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesperidin and Naringin (both)
Number of subjects: 204
Study 18520611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (2 mug/kg per minute)
Number of subjects: 20
Study 18520611 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 20
Study 15777866 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional recovery (defined in terms of neck pain intensity or work disability without medication use)
Number of subjects: 125
Study 15777866 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck pain intensity
Number of subjects: 125
Study 15777866 — intervention group
Group type: EXPERIMENTAL
Intervention: Work disability
Number of subjects: 125
Study 15777866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sick leave
Number of subjects: 125
Study 15777866 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic factors identified by logistic regression analyses
Number of subjects: 125
Study 12452319 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (Ang II) infusion at a constant dose of 50 ng/min
Number of subjects: 36
Study 12452319 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (NA) infusion with increasing doses (2‐256 ng/min)
Number of subjects: 36
Study 12452319 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 36
Study 10515648 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-point (Liver 3) acupuncture
Number of subjects: 56
Study 10515648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 8622117 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 7.5 mg/kg twice daily
Number of subjects: 306
Study 8622117 — intervention group
Group type: COMPARATOR
Intervention: Amikacin 7.5 mg/kg twice daily
Number of subjects: 306
Study 2166857 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal protein diet
Number of subjects: 27
Study 2166857 — intervention group
Group type: COMPARATOR
Intervention: Animal protein diet supplemented with fiber
Number of subjects: 27
Study 2166857 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat load (acute study)
Number of subjects: 27
Study 2166857 — intervention group
Group type: COMPARATOR
Intervention: Soya load (acute study)
Number of subjects: 27
Study 7049782 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 450
Study 7049782 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Dipyridamole
Number of subjects: 450
Study 31944912 — intervention group
Group type: EXPERIMENTAL
Intervention: Group reminiscence therapy for 8 weeks
Number of subjects: 0
Study 31944912 — intervention group
Group type: COMPARATOR
Intervention: Daily activities (Control)
Number of subjects: 0
Study 31389210 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Cyclosporine Nanoemulsion 0.05% (CN)
Number of subjects: 227
Study 31389210 — intervention group
Group type: COMPARATOR
Intervention: Topical Cyclosporine Emulsion 0.05% (CE)
Number of subjects: 227
Study 31389210 — intervention group
Group type: COMPARATOR
Intervention: Diquafosol Sodium 3% (DQ)
Number of subjects: 227
Study 29233954 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB-based educational intervention
Number of subjects: 578
Study 25418605 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose nilotinib 600 mg with midazolam 4 mg
Number of subjects: 37
Study 25418605 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-dose nilotinib 400 mg twice daily with midazolam 2 mg
Number of subjects: 37
Study 24852508 — intervention group
Group type: EXPERIMENTAL
Intervention: IRC VAS interface
Number of subjects: 10
Study 24852508 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimless VAS interface
Number of subjects: 10
Study 21947558 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH)
Number of subjects: 8
Study 19375008 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral anticoagulation therapy (OAT)
Number of subjects: 214
Study 19375008 — intervention group
Group type: COMPARATOR
Intervention: Bridging therapy with low-molecular-weight heparin (nadroparin-calcium)
Number of subjects: 214
Study 17229744 — intervention group
Group type: EXPERIMENTAL
Intervention: Home cueing programme using a prototype cueing device for 3 weeks
Number of subjects: 153
Study 15107192 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg q.h.s.)
Number of subjects: 27
Study 15107192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (q.h.s.)
Number of subjects: 27
Study 15107192 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 27
Study 11544467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (2%)
Number of subjects: 48
Study 11544467 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine (0.05%)
Number of subjects: 48
Study 11544467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9760436 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic fields (EMF) exposure at power-line frequency (50 Hz)
Number of subjects: 63
Study 9760436 — intervention group
Group type: COMPARATOR
Intervention: Control group of 42 workers of radio link stations, aged 23-65 years (median 30 +/- 14), not exposed to EMF
Number of subjects: 63
Study 8157552 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 125 mg
Number of subjects: 20
Study 8157552 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 250 mg
Number of subjects: 20
Study 8157552 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg
Number of subjects: 20
Study 8157552 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 750 mg
Number of subjects: 20
Study 8157552 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir (all doses)
Number of subjects: 20
Study 3064772 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments in the DBCG programme
Number of subjects: 0
Study 3064772 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence-free survival calculation
Number of subjects: 0
Study 3064772 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival calculation
Number of subjects: 0
Study 31675437 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g probenecid (PRO) + 600 mg tenofovir disoproxil fumarate (TDF) / 400 mg emtricitabine (FTC)
Number of subjects: 14
Study 31675437 — intervention group
Group type: COMPARATOR
Intervention: 600 mg TDF / 400 mg FTC on day 1 and 300 mg TDF / 200 mg FTC on days 2 and 3 (C IPERGAY)
Number of subjects: 14
Study 29323459 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy
Number of subjects: 133
Study 29323459 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopy
Number of subjects: 133
Study 28444112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib (60 mg once a day, 21 days on/7 days off) combined with vemurafenib (960 mg twice a day)
Number of subjects: 493
Study 28444112 — intervention group
Group type: COMPARATOR
Intervention: Vemurafenib (960 mg twice a day)
Number of subjects: 493
Study 28444112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib combined with vemurafenib
Number of subjects: 493
Study 26178731 — intervention group
Group type: EXPERIMENTAL
Intervention: 1350 mg encapsulated green tea extract (540 mg GTC) with 50 mg vitamin C, twice daily for 3 months
Number of subjects: 50
Study 26178731 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 3 months
Number of subjects: 50
Study 23946601 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose amitriptyline (10 mg at bedtime) + rabeprazole (20 mg/d)
Number of subjects: 40
Study 23946601 — intervention group
Group type: COMPARATOR
Intervention: Double-dose rabeprazole (20 mg twice daily)
Number of subjects: 40
Study 23946601 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose amitriptyline + rabeprazole
Number of subjects: 40
Study 23946601 — intervention group
Group type: COMPARATOR
Intervention: Double-dose rabeprazole
Number of subjects: 40
Study 22118751 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) supplementation (640 mg polyphenols/d)
Number of subjects: 35
Study 22118751 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 35
Study 18199943 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing with soap and water
Number of subjects: 15
Study 18199943 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing with water alone
Number of subjects: 15
Study 18199943 — intervention group
Group type: EXPERIMENTAL
Intervention: Drying by patting with a towel
Number of subjects: 15
Study 18199943 — intervention group
Group type: EXPERIMENTAL
Intervention: Drying by rubbing with a towel
Number of subjects: 15